Navigation Links
Neurologix Presents New Confirmatory Results for Phase 2 Study of NLX-P101 in Parkinson's Disease to Recombinant DNA Advisory Committee
Date:6/8/2011

oints) with sham treatment. Improved motor control in the NLX-P101 group was seen at one month and continued virtually unchanged throughout the blinded six month study period.  The improvement in UPDRS motor scores from baseline in the NLX-P101 group was significantly greater than sham subjects over the six month study period (p=0.04). Last month, the one year follow-up results of these primary outcomes were presented at the International Neuromodulation Society's 10th World Congress meeting by Neurologix scientific co-founder Michael G. Kaplitt, M.D., Ph.D., Associate Professor of Neurological Surgery at Weill Cornell Medical College. He reported sustained improvement of an average of 8.2 points in the off-medication UPDRS motor score at one year. Furthermore, while 50% of patients at six months achieved previously defined moderate-to-large clinically meaningful symptom improvements (> 9 points in off-medication UPDRS motor score), 63% of patients achieved such results at one year, with an average 14 point, or 37% improvement in off-medication UPDRS motor scores in this group.

The Company's Phase 2 study findings build upon earlier positive results from the NLX-P101 Phase 1 trial, which appeared in 2007 as a cover article in The Lancet and in a second article in the Proceedings of the National Academy of Sciences. Neurologix plans to submit a Phase 3 protocol to the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment later in 2011.

"Neurologix is committed to providing patients a novel, sustained, long-term option for managing and controlling the debilitating conditions of Parkinson's disease," said Clark A. Johnson, President and Chief Executive Officer of Neurologix. "The statistically significant extension of "ON" time, lessening of medication side effects and favorable safety profile in the treated patient group at 12 months are encouraging results that further support NLX-P101 as a viable treatment op
'/>"/>

SOURCE Neurologix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
3. Neurologix Reports Third Quarter 2010 Financial Results
4. Neurologix Completes Additional $7 Million Financing
5. Neurologix Announces First Quarter 2011 Financial Results
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... Telbec/ - Russell Williams , President of ... the 2015-2016 Quebec Budget, noting the fiscal discipline and ... industry. However, the association is concerned about the decline ... government,s intent to strive for a balanced budget this ... Quebec,s economic development is encouraging," said ...
(Date:3/27/2015)... VICTORIA, Texas , March 27, 2015  Victoria Vein ... removal services with the Astanza Duality laser in ... of vein disease as well as advanced laser treatments for ... are entering the tattoo industry to provide more services for ... Surgery has helped many Victoria residents ...
(Date:3/27/2015)... March 27, 2015 A new report from Kalorama ... – Chile , ... top targets for IVD firms.  The healthcare research firm said ... IVD strategies for the Latin American continent with a population ... distributed supply operations. However, the country,s regional economic clout does ...
Breaking Medicine Technology:Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 2Quebec 2015-2016 Budget: Rx&D welcomes fiscal discipline and biopharma working group, but the decrease in government spending on medicines is questioned 3Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4
(Date:3/28/2015)... 28, 2015 Coffee could not only perk ... you from gum disease, researchers have found. , They found ... , Coffee contains antioxidants. Antioxidants fight gum disease. Does coffee, ... at Boston Univ. Henry M. Goldman School of Dental Medicine ... 2014 issue of the Journal of Periodontology. , “This is ...
(Date:3/28/2015)... 2015 With more than 4,500 ... of osteoporosis, osteoarthritis and musculoskeletal diseases gathered here ... be the first time in the 17-year history ... the hot-button topic is an emerging non-pharmaceutical protocol ... scientific principles of Wolff’s law, osteogenic loading at ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 India ... coverage is made available to all visitors who purchase ... immediately. All members are encouraged to purchase the insurance ... avoid lack of proper coverage for pre-existing medical conditions. ... one or two medical conditions with serious consequences to ...
(Date:3/28/2015)... One in three young athletes who ... today at the American Orthopaedic Society for Sports Medicine’s ... long term success of surgery for patients aged 18 ... from 242 patients who underwent ACL reconstruction between 1993 ... FRACS, from North Sydney Orthopaedic and Sports Medicine Centre. ...
(Date:3/28/2015)... 28, 2015 Genomic medicine experts have ... revealing, for the first time, key information for understanding ... read the newly posted story on the Surviving ... of British Columbia, the British Columbia Cancer Agency, and ... reveal underlying molecular alterations and mutations that can lead ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2010-01/yu-stt011110.php,">Chinese . Stress induces ... Yale researchers have discovered. The research, published ... , describes a novel way cancer takes hold ... attack the deadly disease. Until now, most researchers ...
... too little shut-eye, study finds , WEDNESDAY, Jan. 13 (HealthDay ... has on functioning and thinking cannot be reversed by one ... of good sleep can make you feel and operate better ... loss linger much longer. , In fact, "chronic sleep loss ...
... , NEW YORK , ... Eric Spiegel has been named president and CEO of ... expert, starts the position on January 18 . ... Senior Vice President and Senior Partner at Booz & Co. ...
... in the general population use the drug responsibly, study finds ... taking Viagra will lead to sexually risky behavior can relax: ... make men more likely to engage in potentially unhealthy sex. ... a doctor who may worry that prescribing erectile-dysfunction drugs to ...
... climbing, government study finds , WEDNESDAY, Jan. 13 (HealthDay News) ... in the United States may finally be stabilizing instead of ... obesity remain high, with about one-third of Americans still falling ... heavy 6- to 19-year-old boys appear to be increasing. , ...
... around dental implants is far more common than previously realised, ... of Gothenburg, Sweden. Around a quarter of patients loose some ... X-rays of over 600 patients. The more implants a patient ... find loss of supporting bone. Just over a quarter - ...
Cached Medicine News:Health News:Stress triggers tumor formation, Yale researchers find 2Health News:A Good Night's Slumber Won't Reverse Chronic Sleep Loss 2Health News:A Good Night's Slumber Won't Reverse Chronic Sleep Loss 3Health News:Siemens Taps Top Energy Expert as New Head of U.S. Business 2Health News:Siemens Taps Top Energy Expert as New Head of U.S. Business 3Health News:Taking Viagra Won't Spur Risky Sexual Behavior 2Health News: U.S. Obesity Rates Leveling Off, But Still High 2Health News: U.S. Obesity Rates Leveling Off, But Still High 3
Designed to address the specific demands of the busy operating environment, the AL1 Light Source features state-of-the art 180W Xenon lamp technology, providing light output suitable for all endoscop...
LCD monitors....
Standard arthroscope with telescope (4 mm) for large joints....
... Endoscopy Components, LLC offers ... Equipment "Made in Germany". ... manufactured according to ISO ... most excellent design elements ...
Medicine Products: